Press Room

Browse media releases for important annoucements from the Foundation and the Institute.

For all media requests, contact Camille Turbide at camille.turbide@gmail.com or 514 755-5354.

To download the Foundation’s logos, click here.

79 press releases

New data supports development of colchicine for the prevention of acute respiratory distress syndrome

December 3, 2020

The Montreal Heart Institute has announced that colchicine, a widely available low-cost drug, reduces acute lung injury, acute respiratory distress syndrome and respiratory failure in pre-clinical models. The article reporting these results was published yesterday by the Public Library of Science ONE (PLOS ONE).

Colchicine shows promise as a treatment for at-home COVID-19 patients

November 28, 2020

The Montreal Heart Institute today announced that the COLCORONA clinical trial will continue to recruit non-hospitalized adult patients with COVID-19 as recommended by the independent data monitoring committee (DMC), following a second interim analysis.

National Philanthropy Day – The Montreal Heart Institute Foundation honours Sophie Desmarais

November 16, 2020

As part of National Philanthropy Day, the Montreal Heart Institute Foundation is highlighting the invaluable support of Ms. Sophie Desmarais. This great philanthropist, who for many years has been close to the cause of heart diseases, stood out this year for her involvement in the Colcorona clinical trial aimed to confirm the potential of colchicine to fight COVID-19.

Twice as generous thanks to Manulife

November 11, 2020

With the holiday season just around the corner, we’re proud to count on Manulife to give your generosity an even greater impact. Until December 31st, 2020, every donation will be matched by Manulife. This support allows the Institute to finance major discoveries and help its professionals treat more than 68,000 patients every year.

Common hormone could provide the answer to treating atrial fibrillation

November 5, 2020

New research published today in Nature shows that calcitonin, a well-recognized thyroid hormone that helps regulate bone mass and collagen production, is also produced by cells in the heart. This discovery could hold the key to developing new treatments for people with atrial fibrillation (AF), a common and quite problematic heart rhythm disorder.

CQDM funds the development of a novel artificial intelligence tool for cardiovascular clinical trials

November 5, 2020

The CQDM is pleased to announce the launch of a $600,000 collaborative project in biopharma and artificial intelligence (AI) to develop an AI-driven precision medicine tool.

The Montreal Heart Institute stands out at the prestigious European Society of Cardiology congress

August 31, 2020

During the prestigious virtual congress of the European Society of Cardiology (ESC), researchers from the Montreal Heart Institute presented recent data regarding the impact of colchicine on cardiovascular disease.

Sun Life supports Colcorona genetic study

August 26, 2020

Thank you to Sun Life for contributing to the funding of the Montreal Heart Institute's Colcorona genetic sub-study led by Dr. Marie-Pierre Dubé. This study will help to better prevent the complications of COVID-19 by helping to better target effective medical interventions in patients with the disease.

The Montreal Heart Institute Foundation pays tribute to Dr. Martial G. Bourassa with the creation of the Cardiovascular Medicine Innovation Fund

August 6, 2020

It is with sadness that we learned of the passing of Dr. Martial G. Bourassa, a pioneer of cardiology in Quebec. To honour its legacy in cardiology, the MHI Foundation announces the establishment of the new Innovation Fund. This fund will support the most innovative and hopeful cardiovascular medicine projects aimed at fighting cardiovascular diseases.

The Montreal Heart Institute Foundation announces the new André Chagnon Research Chair in Congenital Heart Disease

August 5, 2020

Thanks to a $2 million donation from Sojecci, this new Research Chair will provide a better understanding of the complex issue of sudden death in children and young adults born with congenital heart disease, which is a heart defect present at birth, so that innovative approaches can be developed for the management and care of these patients.